143 related articles for article (PubMed ID: 28050603)
1. New open conformation of SMYD3 implicates conformational selection and allostery.
Spellmon N; Sun X; Xue W; Holcomb J; Chakravarthy S; Shang W; Edwards B; Sirinupong N; Li C; Yang Z
AIMS Biophys; 2017; 4(1):1-18. PubMed ID: 28050603
[TBL] [Abstract][Full Text] [Related]
2. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Sun J; Li Z; Yang N
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
[TBL] [Abstract][Full Text] [Related]
4. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
Chandramouli B; Chillemi G
J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3.
Sirinupong N; Brunzelle J; Doko E; Yang Z
J Mol Biol; 2011 Feb; 406(1):149-59. PubMed ID: 21167177
[TBL] [Abstract][Full Text] [Related]
7. Is MYND Domain-Mediated Assembly of SMYD3 Complexes Involved in Calcium Dependent Signaling?
Zhang Y; Li C; Yang Z
Front Mol Biosci; 2019; 6():121. PubMed ID: 31737645
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
Xu S; Wu J; Sun B; Zhong C; Ding J
Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Sun J; Shi F; Yang N
ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
[No Abstract] [Full Text] [Related]
13. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
[TBL] [Abstract][Full Text] [Related]
15. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
Luo XG; Ding Y; Zhou QF; Ye L; Wang SZ; Xi T
J Biosci Bioeng; 2007 May; 103(5):444-50. PubMed ID: 17609160
[TBL] [Abstract][Full Text] [Related]
16. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination.
Zhang L; Jin Y; Yang H; Li Y; Wang C; Shi Y; Wang Y
Carcinogenesis; 2019 Dec; 40(12):1492-1503. PubMed ID: 31002112
[TBL] [Abstract][Full Text] [Related]
18. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
19. Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
Bai H; Li Y; Gao H; Dong Y; Han P; Yu H
Cytotechnology; 2016 Aug; 68(4):849-59. PubMed ID: 25563599
[TBL] [Abstract][Full Text] [Related]
20. SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Dai B; Wan W; Zhang P; Zhang Y; Pan C; Meng G; Xiao X; Wu Z; Jia W; Zhang J; Zhang L
Oncol Rep; 2015 Nov; 34(5):2722-30. PubMed ID: 26328527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
